Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
49.53
+1.47 (3.06%)
At close: Jun 9, 2025, 4:00 PM
49.55
+0.02 (0.04%)
After-hours: Jun 9, 2025, 7:41 PM EDT
Guardant Health Employees
As of December 31, 2024, Guardant Health had 2,021 total employees, including 1,999 full-time and 22 part-time employees. The number of employees increased by 242 or 13.60% compared to the previous year.
Employees
2,021
Change (1Y)
242
Growth (1Y)
13.60%
Revenue / Employee
$382,977
Profits / Employee
-$206,109
Market Cap
6.14B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
GH News
- 13 hours ago - New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer - Business Wire
- 6 days ago - Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday? - Benzinga
- 6 days ago - FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test - Business Wire
- 7 days ago - National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening - Business Wire
- 7 days ago - SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer - Business Wire
- 9 days ago - In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions - Business Wire
- 13 days ago - Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test - Business Wire
- 18 days ago - Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting - Business Wire